Semaglutide helps obese lose weight with the amount of 0.4 mg on daily basis through the subcutaneous injections than the placebo treatment, according to the latest analysis conducted on adults with obesity.
In the latest research, the participated obese adults, who were treated with semaglutide, lost nearly 13% of their body weight just in the second phase trial after 52 weeks. The results in the obese adults treated with semaglutide have been found to be quite more effective as compared to those adults went through the placebo treatment, as they just lost around 2.3 per cent of their body weight.
Leading author of the study, Professor of Psychiatry and Behavioral Sciences for the Medical University of South Carolina in Charleston and Director of the Weight Management Center, Dr. Patrick M. O’Neil said in a statement that, “This randomized study of weight loss induced with semaglutide in people with obesity but without diabetes has shown the highest weight reductions yet seen for any pharmaceutical intervention.”
Findings of the research were disclosed during the presentation of the study focused on the efficacy and safety of the semaglutide in the form of potential therapy to be attempted on the adults suffering from obesity, at the 100th annual meeting of the Endocrine Society (ENDO), in Chicago.
“In conclusion, in combination with dietary and physical activity counseling, all SEMA doses from 0.05 to 0.4 mg daily were tolerated and resulted in dose-related reductions in body weight that were superior to PBO among people with obesity without diabetes”, Dr. O’Neil added, “I am encouraged by these results and look forward to seeing data from upcoming phase 3 trials to better understand how semaglutide may play a role in the treatment of obesity.”